Tianjin Medical University Cancer Institute and Hospital: Carcinoma, Hepatocellular trials

The registry lists 40 Carcinoma, Hepatocellular studies with Tianjin Medical University Cancer Institute and Hospital as lead sponsor. 25 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 29Phase 3 1Phase 4 1No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular CarcinomaRecruitingNCT07840092
• Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCCRecruitingNCT07801287Phase 2
• Risk Stratification and Proactive Nursing Intervention for Acute Kidney Injury Following Interventional Therapy in Patients With Liver CancerNot yet recruitingNCT07681817Not applicable
• The DoHAICs Study Expansion PhaseNot yet recruitingNCT07584018Phase 2
• Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaRecruitingNCT07560488Phase 2
• Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow MarginNot yet recruitingNCT07518706Phase 2
• A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence RiskNot yet recruitingNCT07515469Phase 2
• A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of RecurrenceRecruitingNCT07475026Phase 3
• Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07157306Phase 2
• Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line TreatmentNot yet recruitingNCT07078305Phase 2
• The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world StudyNot yet recruitingNCT07078292
• FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular CarcinomaRecruitingNCT07012798Phase 2
• Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular CarcinomaNot yet recruitingNCT06867432Phase 2
• Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular CarcinomaNot yet recruitingNCT06512467Phase 2
• TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant TumorsRecruitingNCT06487663Not applicable
• Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.RecruitingNCT06375486Phase 2
• Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) PatientsRecruitingNCT06370065Phase 2
• Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety StudyRecruitingNCT06301399Phase 2
• H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein ThrombosisNot yet recruitingNCT05872841Phase 2
• HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular CarcinomaRecruitingNCT05864755Phase 2
• Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyRecruitingNCT05856864Phase 1
• HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular CarcinomaNot yet recruitingNCT05821361Phase 2
• Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT05616390Phase 2
• Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular CarcinomaNot yet recruitingNCT05582109Phase 2
• Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaRecruitingNCT05519410Phase 2
• Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVIActive, not recruitingNCT07658105Phase 2
• Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular CarcinomaSuspendedNCT06405061Phase 2
• HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular CarcinomaActive, not recruitingNCT05621499Not applicable
• Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular CarcinomaStatus unknownNCT05166772Phase 2
• HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCCStatus unknownNCT05029973Phase 2
• Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaStatus unknownNCT04834986Phase 2
• Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaCompletedNCT04701060Phase 2
• PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCCStatus unknownNCT04273100Phase 2
• Study of Apatinib Combined With TACE in Advance Hepatocellular CarcinomaStatus unknownNCT03398122Not applicable
• Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)Status unknownNCT03046979Phase 2
• Metformin Plus Sorafenib for Advanced HCCStatus unknownNCT02672488Phase 2
• Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnifeStatus unknownNCT02363218Phase 2
• A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular CarcinomaStatus unknownNCT01758679Phase 4
• Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG)Status unknownNCT01393197Not applicable
• Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular CarinomasStatus unknownNCT01393093Not applicable